[PDF] Top 20 The cell cycle checkpoint inhibitors in the treatment of leukemias
Has 10000 "The cell cycle checkpoint inhibitors in the treatment of leukemias" found on our website. Below are the top 20 most common "The cell cycle checkpoint inhibitors in the treatment of leukemias".
The cell cycle checkpoint inhibitors in the treatment of leukemias
... degeneration, immunodeficiency, radiation sensitivity, chromosomal instability, and cancer pre-disposition [38, 39]. Mutations in ATM pre-dispose A-T patients to the development of lymphoid neoplasms, with a risk for ... See full document
14
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
... both leukemias and lymphomas, BET inhibi- tion preclinically appears to enhance the antiproliferative effects of various therapies in current use for these ... See full document
11
Anticancer drug targets: cell cycle and checkpoint control
... kinase inhibitors. As new inhibitors are developed, it will be important for their medical application that their potency extend to the subnanomolar ...Additional checkpoint abrogators, aimed at ... See full document
10
Nek family of kinases in cell cycle, checkpoint control and cancer
... assembly checkpoint (SAC) preventing progression to anaphase ...of cell division, as cells that are treated with pharmacological inhibitors of the SAC continue to progress through mitosis but arrest ... See full document
10
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... of treatment and correlates with dosage but can occur as late as 2 years after initialization of treatment [11, ...immune checkpoint inhibitors are so far lacking in the ... See full document
8
<p>Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives</p>
... cancer cell death including apoptosis, necroptosis, and pyroptosis as forms of programmed cell death (PCD) and necrosis as a type of non-PCD (Figure ...) cell – and CD8 + ... See full document
10
Prospects for combining immune checkpoint blockade with PARP inhibition
... cancer cell is derived from accumulated somatic ...Immune checkpoint inhibitors block negative co-stimulatory signals such as programmed cell death-1 and cytotoxic T-lymphocyte-associated ... See full document
12
Immune checkpoint inhibitors in the treatment of virus-associated cancers
... combine with other carcinogenic infectious factors [51]. A systematic review [27] was conducted to summarize the efficacy of ICIs therapy in HIV-positive cancers. Among 34 patients with known paired pretreatment and ... See full document
10
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
... immune checkpoint inhibitors compared with docetaxel in patients with platinum-refractory advanced ...anti-PD-1 inhibitors) [13], recommendation of a given treatment over another is not yet ... See full document
7
Immunotherapy for lethal prostate cancer.
... Programmed cell death 1 (PD-1) blocking agents have become crucial components of the treatment of deadly diseases such as metastatic lung cancer and melanoma, but have also changed the treatment ... See full document
7
Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
... Immune checkpoint inhibitors (CPIs) are highly effective against a range of advanced malignancies, but are also associated with treatment-limiting inflammatory toxic- ities termed “immune-related ... See full document
10
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
... immune-checkpoint inhibitors can help overcome T-cell dysfunction in cancer ...programmed cell death protein 1, T-cell exhaustion, T-cell immunoglobulin and mucin domain 3, ... See full document
20
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
... immune cell to infiltrate into the tumor, 4) the inhibitory state of the tumor microenvironment such as absence of checkpoints, 5) absence of soluble inhibitors (interleukin 6 [IL-6], C-reactive protein), ... See full document
9
Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
... to checkpoint inhibitors and requires new approaches designed to bring T-cell into the tumor such as dual PD1/PD-L1 and CTLA-4 blockade, use of vaccine or agents that induce T-cell function ... See full document
16
Checkpoint inhibitors in the treatment of urological malignancies
... Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) ... See full document
9
Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
... correlated with PD-L1 expression, and mutated tissues without T cell infiltration reflected no immunogenic toler- ance. In addition, they also found that patients with lung cancer with KRAS mutations had high ... See full document
10
An overview of Cdk1-controlled targets and processes
... and checkpoint proteins that otherwise might recognize the chromosome ends as DNA double-strand breaks ...is cell cycle dependent, and recently it was shown that Cdk1-medi- ated phosphorylation of ... See full document
41
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
... cancer cell lines, a decrease in cell viability and in phospho-biomarker expression was ...following treatment with AZD7328, cell viability was less affected in the patient-derived cultures ... See full document
17
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
... directed treatment, well defined in the world of leukemia and lymphoma, is also established in certain solid tumors such as breast cancer, where estrogen and progesterone receptor positivity has long-guided ... See full document
10
Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study
... these cell lines exhibited a small decrease in survival with radiation doses between 0 and 6 Gy, yet an exponential decrease in survival ensued at doses over 6 ...for treatment of both primary and meta- ... See full document
6
Related subjects